Clinical Trials for Prostate Cancer

A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors

TrialFetch AI summary: Adults with advanced, measurable solid tumors and assessable MUC1 and/or HER3 expression are eligible to receive DM002, a bispecific antibody-drug conjugate targeting MUC1 and HER3, given intravenously every three weeks.

ClinicalTrials.gov ID: NCT06751329

A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors

TrialFetch AI summary: This trial enrolls adults with locally advanced or metastatic solid tumors—especially those with Wnt pathway activating mutations such as APC or CTNNB1—including select colorectal, liver, desmoid, and prostate cancers, testing the oral β-catenin:TCF4 inhibitor FOG-001 as monotherapy or in combination with standard regimens (e.g., mFOLFOX-6 plus bevacizumab, nivolumab, or trifluridine/tipiracil plus bevacizumab). Eligible patients must have ECOG 0-1 and no significant bone, CNS, cardiac disease, or active IBD.

ClinicalTrials.gov ID: NCT05919264

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)

TrialFetch AI summary: Adults with DLL3-expressing advanced/metastatic neuroendocrine carcinomas (including SCLC, LCNEC, and extrapulmonary NEC; predominant ≥50% neuroendocrine component) receive peluntamig (PT217), a bispecific anti-DLL3/CD47 IgG designed to promote macrophage phagocytosis and ADCC, as monotherapy or combined with carboplatin/etoposide, paclitaxel, and/or atezolizumab. Cohorts include relapsed/refractory disease and line-specific settings such as platinum-sensitive second line and ES-SCLC first-line or post-induction with atezolizumab.

ClinicalTrials.gov ID: NCT05652686

(ID-COMET) A Randomized Phase III Trial of Immediate Versus Six-Month Delayed Comprehensive Treatment of 1-10 Oligometastatic Tumors With or Without Synchronous Primary

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults and children (ECOG 0–3) with newly diagnosed oligometastatic lung, colorectal, or prostate cancer (1–10 lesions; brain mets excluded) are randomized to immediate stereotactic ablative radiotherapy (SABR) to all treatable sites plus standard systemic therapy versus initial standard therapy with SABR delayed ~6 months; a separate cohort allows immediate SABR for broader oligometastatic/oligoprogressive disease. Compares survival/ADT-free survival and safety/quality of life while standard systemic regimens are given per tumor type.

ClinicalTrials.gov ID: NCT06563388

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

TrialFetch AI summary: Adults with advanced/metastatic solid tumors (endometrial, gastric, mCRPC, ovarian, colorectal, urothelial, biliary) receive datopotamab deruxtecan (anti‑TROP2 antibody–drug conjugate delivering a topoisomerase I inhibitor) as monotherapy or combined with agents such as capecitabine/5‑FU, bevacizumab ± platinum, prednisone (mCRPC), platinum in urothelial cancer, or bispecific PD‑1/CTLA‑4 (volrustomig) or PD‑1/TIGIT (rilvegostomig) immunotherapies. Key exclusions include active/untreated CNS disease, prior TROP2- or deruxtecan-based ADCs, significant ILD/pneumonitis history, and uncontrolled infections/comorbidities.

ClinicalTrials.gov ID: NCT05489211

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adults with advanced solid tumors or lymphomas, including molecularly defined cohorts such as ARID1A-mutant endometrial/ovarian clear cell and other solid tumors, BAP1-loss mesothelioma, PTCL/DLBCL (including EZH2-mutant), and mCRPC. Investigational therapy is tulmimetostat (CPI-0209), an oral dual EZH2/EZH1 inhibitor, given as monotherapy across cohorts and combined with enzalutamide in mCRPC.

ClinicalTrials.gov ID: NCT04104776

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge

TrialFetch AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma, asymptomatic/mildly symptomatic, after exactly one prior ARPI (no small cell/neuroendocrine features; excluding brain or liver metastases), are randomized to BMS-986365 (gridegalutamide), an oral cereblon-recruiting androgen receptor degrader/antagonist, versus investigator’s choice of docetaxel/prednisone or a second ARPI (abiraterone/prednisone or enzalutamide). Primary endpoint is radiographic PFS with blinded central review.

ClinicalTrials.gov ID: NCT06764485

Carboplatin and Cabazitaxel Versus 177Lu-PSMA-617 in Patients With Aggressive, Metastatic Castrate-resistant Prostate Cancer (CATCH-177)

TrialFetch AI summary: Adults with aggressive, PSMA-PET–positive mCRPC after at least one AR pathway inhibitor (often post-docetaxel) are randomized to cabazitaxel plus carboplatin versus 177Lu-PSMA-617 radioligand therapy (binds PSMA to deliver beta-emitting lutetium-177). Eligible patients have high-risk features (e.g., visceral disease, ≥5 bone mets, lower PSMA SUVmean, or TP53/PTEN/RB1 alterations) and ECOG 0–2.

ClinicalTrials.gov ID: NCT06738303

A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

TrialFetch AI summary: Men with progressive metastatic castration‑resistant prostate adenocarcinoma after one next‑generation AR pathway inhibitor, ECOG 0–1, receive gedatolisib (investigational pan‑class I PI3K/mTORC1/2 inhibitor) plus darolutamide. Excludes prior PI3K/AKT/mTOR therapy or mCRPC chemo/radiopharmaceuticals; continued ADT required.

ClinicalTrials.gov ID: NCT06190899

A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

TrialFetch AI summary: Adults with metastatic castration-resistant prostate cancer progressing after ADT and 1–2 prior AR pathway inhibitors (no prior taxane for mCRPC) are randomized to ifinatamab deruxtecan (I-DXd), a B7-H3–targeted antibody–drug conjugate delivering a topoisomerase I inhibitor, versus docetaxel plus prednisone. Key exclusions include prior steroid-requiring ILD/pneumonitis and significant cardiovascular disease; primary endpoints are OS and rPFS.

ClinicalTrials.gov ID: NCT06925737